This inventor holds 6 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2006-2014.
Company Filing History:
Years Active: 2006-2014
Title: Richard A. Rampulla: Innovator in Heterocyclic CETP Inhibitors
Introduction
Richard A. Rampulla is a notable inventor based in Flemington, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic CETP inhibitors. With a total of 6 patents to his name, Rampulla's work has had a considerable impact on medical research and drug development.
Latest Patents
Among his latest patents are innovative compounds described as heterocyclic CETP inhibitors. These include compounds of formula Ia and Ib, wherein A, B, C, and R are detailed in the patent documentation. His research focuses on the potential therapeutic applications of these compounds in treating various health conditions.
Career Highlights
Richard A. Rampulla is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role involves extensive research and development, contributing to the advancement of new therapeutic solutions. His expertise in the field has positioned him as a key player in pharmaceutical innovation.
Collaborations
Throughout his career, Rampulla has collaborated with several esteemed colleagues, including Mark E. Salvati and Jacques Y. Roberge. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical compounds.
Conclusion
Richard A. Rampulla's contributions to the field of pharmaceuticals, particularly through his patents on heterocyclic CETP inhibitors, highlight his role as a significant inventor. His work continues to influence the landscape of medical research and drug development.